A Comparative Analysis of Individual RAS Mutations in Cancer Biology

被引:158
作者
Munoz-Maldonado, Carmen [1 ,2 ]
Zimmer, Yitzhak [1 ,2 ]
Medova, Michaela [1 ,2 ]
机构
[1] Bern Univ Hosp, Dept Radiat Oncol, Inselspital, Bern, Switzerland
[2] Univ Bern, Dept BioMed Res, Radiat Oncol, Bern, Switzerland
来源
FRONTIERS IN ONCOLOGY | 2019年 / 9卷
关键词
RAS mutations; RAS profile; RAS-mutated cancers; treatment responses; RAS-related omics; GTP; GDP binding; RAS signaling; rare codons; ONCOGENIC K-RAS; H-RAS; N-RAS; KRAS MUTATIONS; GENE; PROLIFERATION; ASSOCIATION; ACTIVATION; GROWTH; MOUSE;
D O I
10.3389/fonc.2019.01088
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In human cells, three closely related RAS genes, termed HRAS, KRAS, and NRAS, encode four highly homologous proteins. RAS proteins are small GTPases involved in a broad spectrum of key molecular and cellular activities, including proliferation and survival among others. Gain-of-function missense mutations, mostly located at codons 12, 13, and 61, constitutively activate RAS proteins and can be detected in various types of human cancers. KRAS is the most frequently mutated, followed by NRAS and HRAS. However, each isoform exhibits distinctive mutation frequency at each codon, supporting the hypothesis that different RAS mutants may lead to distinct biologic manifestations. This review is focused on the differences in signaling and phenotype, as well as on transcriptomics, proteomics, and metabolomics profiles related to individual RAS-mutated variants. Additionally, association of these mutants with particular targeted outcomes and rare mutations at additional RAS codons are discussed.
引用
收藏
页数:22
相关论文
共 79 条
  • [1] Characterization of a novel oncogenic K-ras mutation in colon cancer
    Akagi, Kiwamu
    Uchibori, Ryosuke
    Yamaguchi, Kensei
    Kurosawa, Keiko
    Tanaka, Yoichiro
    Kozu, Tomoko
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2007, 352 (03) : 728 - 732
  • [2] American Society of Clinical Oncology Provisional Clinical Opinion: Testing for KRAS Gene Mutations in Patients With Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy
    Allegra, Carmen J.
    Jessup, J. Milburn
    Somerfield, Mark R.
    Hamilton, Stanley R.
    Hammond, Elizabeth H.
    Hayes, Daniel F.
    McAllister, Pamela K.
    Morton, Roscoe F.
    Schilsky, Richard L.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (12) : 2091 - 2096
  • [3] Molecular Pathways: Targeting RAC-p21-Activated Serine-Threonine Kinase Signaling in RAS-Driven Cancers
    Baker, Nicole M.
    Chow, Hoi Yee
    Chernoff, Jonathan
    Der, Channing J.
    [J]. CLINICAL CANCER RESEARCH, 2014, 20 (18) : 4740 - 4746
  • [4] PKC regulates a farnesyl-electrostatic switch on K-Ras that promotes its association with Bcl-XL on mitochondria and induces apoptosis
    Bivona, TG
    Quatela, SE
    Bodemann, BO
    Ahearn, IM
    Soskis, MJ
    Mor, A
    Miura, J
    Wiener, HH
    Wright, L
    Saba, SG
    Yim, D
    Fein, A
    Perez de Castro, I
    Li, C
    Thompson, CB
    Cox, AD
    Philips, MR
    [J]. MOLECULAR CELL, 2006, 21 (04) : 481 - 493
  • [5] KRAS mutation status is not predictive for objective response to anti-EGFR treatment with erlotinib in patients with advanced pancreatic cancer
    Boeck, Stefan
    Jung, Andreas
    Laubender, Ruediger P.
    Neumann, Jens
    Egg, Rosalind
    Goritschan, Clara
    Ormanns, Steffen
    Haas, Michael
    Modest, Dominik P.
    Kirchner, Thomas
    Heinemann, Volker
    [J]. JOURNAL OF GASTROENTEROLOGY, 2013, 48 (04) : 544 - 548
  • [6] Role of protein kinase CK2 in antitumor drug resistance
    Borgo, Christian
    Ruzzene, Maria
    [J]. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2019, 38 (1)
  • [7] KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma
    Bournet, Barbara
    Muscari, Fabrice
    Buscail, Camille
    Assenat, Eric
    Barthet, Marc
    Hammel, Pascal
    Selves, Janick
    Guimbaud, Rosine
    Cordelier, Pierre
    Buscail, Louis
    [J]. CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY, 2016, 7 : E157
  • [8] Comparative metabolomics profiling of isogenic KRAS wild type and mutant NSCLC cells in vitro and in vivo
    Brunelli, Laura
    Caiola, Elisa
    Marabese, Mirko
    Broggini, Massimo
    Pastorelli, Roberta
    [J]. SCIENTIFIC REPORTS, 2016, 6
  • [9] Capturing the metabolomic diversity of KRAS mutants in non-small-cell lung cancer cells
    Brunelli, Laura
    Caiola, Elisa
    Marabese, Mirko
    Broggini, Massimo
    Pastorelli, Roberta
    [J]. ONCOTARGET, 2014, 5 (13) : 4722 - 4731
  • [10] Mutation-Specific RAS Oncogenicity Explains NRAS Codon 61 Selection in Melanoma
    Burd, Christin E.
    Liu, Wenjin
    Huynh, Minh V.
    Waqas, Meriam A.
    Gillahan, James E.
    Clark, Kelly S.
    Fu, Kailing
    Martin, Brit L.
    Jeck, William R.
    Souroullas, George P.
    Darr, David B.
    Zedek, Daniel C.
    Miley, Michael J.
    Baguley, Bruce C.
    Campbell, Sharon L.
    Sharpless, Norman E.
    [J]. CANCER DISCOVERY, 2014, 4 (12) : 1418 - 1429